US 11,866,785 B2
Tumor specific antibodies and T-cell receptors and methods of identifying the same
Gregory C. Ippolito, Austin, TX (US); Jonathan R. Mcdaniel, Austin, TX (US); William N. Voss, Austin, TX (US); and George Georgiou, Austin, TX (US)
Assigned to Board of Regents, The University of Texas System, Austin, TX (US)
Appl. No. 16/759,371
Filed by BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
PCT Filed Oct. 29, 2018, PCT No. PCT/US2018/057961
§ 371(c)(1), (2) Date Apr. 27, 2020,
PCT Pub. No. WO2019/084538, PCT Pub. Date May 2, 2019.
Claims priority of provisional application 62/578,230, filed on Oct. 27, 2017.
Prior Publication US 2020/0270704 A1, Aug. 27, 2020
Int. Cl. C12Q 1/6886 (2018.01); C07K 16/30 (2006.01); C12Q 1/6881 (2018.01)
CPC C12Q 1/6886 (2013.01) [C07K 16/3069 (2013.01); C12Q 1/6881 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01)] 11 Claims
 
1. An isolated monoclonal antibody, wherein the antibody specifically binds to NY-ESO-1 and comprises:
(i) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 1, a VHCDR2 amino acid sequence of SEQ ID NO: 3, and a VHCDR3 amino acid sequence of SEQ ID NO: 16; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 10, a VLCDR2 amino acid sequence of SEQ ID NO: 12, and a VLCDR3 amino acid sequence of SEQ ID NO: 17;
(ii) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 1, a VHCDR2 amino acid sequence of SEQ ID NO: 3, and a VHCDR3 amino acid sequence of SEQ ID NO: 6; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 10, a VLCDR2 amino acid sequence of SEQ ID NO: 12, and a VLCDR3 amino acid sequence of SEQ ID NO: 13;
(iii) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 1, a VHCDR2 amino acid sequence of SEQ ID NO: 4, and a VHCDR3 amino acid sequence of SEQ ID NO: 7; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 11, a VLCDR2 amino acid sequence of SEQ ID NO: 12, and a VLCDR3 amino acid sequence of SEQ ID NO: 14;
(iv) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 1, a VHCDR2 amino acid sequence of SEQ ID NO: 4, and a VHCDR3 amino acid sequence of SEQ ID NO: 8; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 11, a VLCDR2 amino acid sequence of SEQ ID NO: 12, and a VLCDR3 amino acid sequence of SEQ ID NO: 14;
(v) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 2, a VHCDR2 amino acid sequence of SEQ ID NO: 5, and a VHCDR3 amino acid sequence of SEQ ID NO: 9; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 11, a VLCDR2 amino acid sequence of SEQ ID NO: 12, and a VLCDR3 amino acid sequence of SEQ ID NO: 15;
(vi) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 18, a VHCDR2 amino acid sequence of SEQ ID NO: 21, and a VHCDR3 amino acid sequence of SEQ ID NO: 24; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 26, a VLCDR2 amino acid sequence of SEQ ID NO: 28, and a VLCDR3 amino acid sequence of SEQ ID NO: 31;
(vii) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 19, a VHCDR2 amino acid sequence of SEQ ID NO: 22, and a VHCDR3 amino acid sequence of SEQ ID NO: 24; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 26, a VLCDR2 amino acid sequence of SEQ ID NO: 29, and a VLCDR3 amino acid sequence of SEQ ID NO: 32;
(viii) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 20, a VHCDR2 amino acid sequence of SEQ ID NO: 23, and a VHCDR3 amino acid sequence of SEQ ID NO: 25; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 27, a VLCDR2 amino acid sequence of SEQ ID NO: 30, and a VLCDR3 amino acid sequence of SEQ ID NO: 33;
(ix) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 34, a VHCDR2 amino acid sequence of SEQ ID NO: 35, and a VHCDR3 amino acid sequence of SEQ ID NO: 44; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 38, a VLCDR2 amino acid sequence of SEQ ID NO: 40, and a VLCDR3 amino acid sequence of SEQ ID NO: 42; or
(x) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 34, a VHCDR2 amino acid sequence of SEQ ID NO: 36, and a VHCDR3 amino acid sequence of SEQ ID NO: 37; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 39, a VLCDR2 amino acid sequence of SEQ ID NO: 41, and a VLCDR3 amino acid sequence of SEQ ID NO: 43.